Promising emerging agents for triple negative breast cancer

8 April 2014

Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development target only specific subsets of patients, notes a new report from Decision Resources.

The two novel emerging therapies niraparib (from US oncology drug developer Tesaro [Nasdaq: TSRO]) and Xtandi (enzalutamide; Medivation [Nasdaq: MDVN]/Astellas [TYO- 4503]) are set to offer efficacy advantages over currently available agents in the BRCA1/2-mutation positive and androgen receptor triple negative patient populations, respectively.

Other key findings from the DecisionBase 2014 report titled Breast Cancer (Triple-Negative, Advanced/Metastatic): What Attributes will Distinguish Emerging Therapies in the Eyes of Oncologists and Payers?:

25% of oncologists would prescribe niraparib to a median of 50% of their first-line BRCA1/2-mutation positive triple negative breast cancer patients;
oncologists indicate neurological toxicity as a high area of unmet need; and
oncologists weigh increases in efficacy over cost for potential emerging therapies

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK